BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. We are currently developing a PET-imaging diagnostic for liver fibrosis and a combined PET-imaging diagnostic and targeted radiotherapeutic for advanced CMS4 colon cancer. Our platform and drug development engine is based on proprietary PDGF-ß-receptor medium affinity binding bicyclic peptides and PDGF-ß-receptor high affinity VHH nanobodies.